| INTRODUCTION
Current treatment guidelines 1,2 recommend metformin as first-line treatment for adults with type 2 diabetes who cannot attain glycaemic goals with lifestyle modifications, and metformin remains the most widely prescribed oral antidiabetic (OAD) worldwide. 3 Metformin reduces fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) by inhibiting hepatic gluconeogenesis and decreasing endogenous glucose production and intestinal glucose absorption, and may also lead to increased peripheral insulin sensitivity. 4 Metformin has many benefits; it reduces glycated haemoglobin (HbA1c) by 1%-2%, 5 and the antihyperglycaemic effects of metformin monotherapy are comparable to those obtained with sulfonylureas and thiazolidinediones. 6, 7 Chronic metformin treatment is associated with low risks of weight increase and hypoglycaemia. 8 However, as diabetes progresses, metformin monotherapy may be insufficient to obtain or maintain glycaemic goals. However, as it acts via different mechanisms, metformin can achieve synergistic effects when combined with other antihyperglycaemic agents. 9, 10 In China, the estimated overall prevalence of type 2 diabetes among adults in 2013 was 10.9%. 11 However, among patients diagnosed with diabetes, only 25.8% received treatment for diabetes, and only 39.7% of those treated had adequate glycaemic control. 11 In many cases, the prescribed treatment regimens were not standardized. The most commonly prescribed therapies reported were OAD monotherapy, accounting for 51.2%, insulin monotherapy, accounting for 21.8%, and insulin in combination with OAD, accounting for 27%.
12 Surprisingly, almost half of the patients in China for whom insulin was prescribed did not initially receive a prescription for any OAD. 12 Compared with western countries, most patients in China received prescriptions for premixed insulin, such as biphasic insulin aspart 30 (BIAsp 30). 13 In clinical practice, the main disadvantages of insulin treatment are weight gain and risk of hypoglycaemia. The combination of metformin and insulin can lead to decreased blood glucose with a lower dose of insulin, possibly resulting in a more stable blood glucose level and less weight gain. 14, 15 
| Randomization
After screening, eligible patients were randomized at a 1:1 ratio to BIAsp 30 plus metformin or BIAsp 30. Patients were stratified by HbA1c level and BMI, using an interactive voice response system at baseline.
| Treatment and titration
During the titration phase, doses of metformin and insulin were adjusted to achieve targets of FPG 4.4-7.0 mmoL/L and 2-hour PPG < 10 mmoL/L (180 mg/dL).
The initial dose of metformin in the titration phase was 500 or 850 mg once daily and was titrated to a maximum tolerated dose of ≤2500 mg/d. For the 500 mg dose, 500 mg was administered twice daily (breakfast and dinner) for 1 week, followed by three times daily (breakfast, lunch and dinner) for 1 week. If patients tolerated 1500 mg/d, the dose of metformin was titrated to either 500 mg at breakfast, 500 mg at lunch and 1000 mg at dinner for 1 week or to 1000 mg at breakfast and 1000 mg at dinner for 1 week. If patients tolerated 2000 mg/d, the dose of metformin was titrated to 1000 mg at breakfast, 500 mg at lunch and 1000 mg at dinner for 1 week, after which the maximum tolerated dose (or 500 mg at breakfast, 1000 mg at lunch and 1000 mg at dinner) was administered for 12 weeks. For the 850 mg dose, 850 mg was administered with lunch for 2 weeks, after which 850 mg was administered twice daily (lunch and dinner) for 2 weeks and, finally, 850 mg was administered thrice daily (breakfast, lunch and dinner), after which the maximum tolerated dose was administered for 12 weeks (≤ 2550 mg). 
| Statistical analysis
For a type I error of 0.025 and an estimated dropout rate of 15%, we planned for the enrolment of 256 patients to achieve a power of 0.9 in one-sided tests. The screening population was all patients who provided informed consent and received demographic assessments and/or baseline screening, regardless of the condition of randomization and treatment. Study populations were the intention-to-treat set (ITTS), defined as patients who were expected to receive treatment; the per protocol set, defined as patients who were fully compliant with the study protocol, had no major protocol violations and completed measures of primary endpoints; and the safety analysis set, defined as patients who received medication at least once.
Continuous variables were summarized using descriptive statis- Patients were excluded from analysis in the monotherapy group for use of prohibited medications (n = 2) and for not completing primary endpoint assessments (n = 20).
| Baseline demographic and clinical characteristics (ITTS)
The (Table 3) . Mean changes from baseline to week 16 in FPG and PPG are also shown in Table 3 .
| Secondary efficacy endpoints
During the treatment period, the total daily insulin dose in the BIAsp 30 plus metformin group was significantly lower than that in the BIAsp 30 group, as was the increase in weight ( These results are consistent with those of similar studies conducted in other regions. In one study, 17 twice-daily BIAsp 30 plus metformin provided better glycaemic control to insulin-naïve patients with type 2 diabetes than once-daily insulin glargine plus glimepiride.
In another study, BIAsp 30 plus metformin achieved better glycaemic control than glibenclamide plus metformin. 15 However, these comparisons should be interpreted carefully because of differences in study designs, comparator arms and populations.
In our study, both groups presented improvements in HbA1c, reported that patients with type 2 diabetes who received placebo and insulin gained significantly more weight than those treated with metformin over 4.3 years. The differences in weight gain between groups could not be explained by reduced energy intake. 24 We also compared changes in body weight across three BMI subgroups and found a trend towards weight reduction in the overweight and obese subgroups. Importantly, we found that the effect of BIAsp 30 plus metformin on HbA1c was not related to baseline BMI levels, which is consistent with results of a previous study in a Chinese population. 25 As in previous studies, it is likely that metformin helped to reduce weight gain in our study, at least in part, by increasing insulin sensitivity.
A large observational study in China found that premixed insulin improved quality of life for type 2 diabetes patients. 26 In the present study, patients treated with BIAsp 30 plus metformin had significantly higher patient satisfaction scores than patients receiving BIAsp 30 alone. Given that weight gain was lower in patients receiving BIAsp 30 plus metformin, it is possible that this contributed to the higher satisfaction level in that group.
Insulin treatment is associated with higher incidence of hypoglycaemia in elderly individuals, and patients using insulin have the highest rates of self-reported severe hypoglycaemia (25% in patients using insulin for >5 years). 27 In the present study, the number of patients who experienced hypoglycaemic episodes was similarly low in both groups. However, the only severe hypoglycaemic event occurred in the monotherapy group. Although a significantly higher frequency of gastrointestinal events occurred in the combination group than in the monotherapy group, most events were mild/moderate and resolved promptly with symptomatic treatment. As these AEs are well-known effects of metformin, 3, 4 no new safety concerns were raised in this study.
China has a considerably higher usage of premixed insulin/insulin analogues than developed countries. A shortcoming of premixed insulin is that its intermediate activity does not reflect physiological pancreatic insulin secretion, 28 which may lead to increased insulin levels and high incidences of hypoglycaemia, and subsequently to poor compliance. In this study, metformin use was associated with a decrease in the daily dose of insulin and better glycaemic control. The present results support recommendations of the Chinese guidelines and provide robust evidence that will prove useful in clinical practice.
This study has some limitations. Factors such as diet control, exercise and mental and psychological conditions that may affect the treatment of type 2 diabetes patients were not considered. The sample size was also relatively small, with only 257 participants.
The LS mean treatment difference in HbA1c was 0.67% between the two groups; however, theoretically, the combination therapy should be superior. This hypothesis requires further investigation in a larger sample. Additionally, the titration of insulin was insufficiently aggressive, although this approach is considered clinically appropriate.
In conclusion, this study demonstrated the non-inferiority of These results are relevant to clinical practice in a setting such as China, where premixed insulin accounts for a large proportion of prescribed treatment regimens.
